ID   DYRK3_HUMAN             Reviewed;         588 AA.
AC   O43781; D3DT79; Q7Z752; Q9HBY6; Q9HBY7;
DT   27-APR-2001, integrated into UniProtKB/Swiss-Prot.
DT   26-JUN-2007, sequence version 3.
DT   12-OCT-2022, entry version 192.
DE   RecName: Full=Dual specificity tyrosine-phosphorylation-regulated kinase 3;
DE            EC=2.7.12.1 {ECO:0000269|PubMed:23415227, ECO:0000269|PubMed:29634919, ECO:0000269|PubMed:29973724, ECO:0000269|PubMed:9748265};
DE   AltName: Full=Regulatory erythroid kinase {ECO:0000303|PubMed:10779429};
DE            Short=REDK {ECO:0000303|PubMed:10779429};
GN   Name=DYRK3 {ECO:0000312|HGNC:HGNC:3094};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), CATALYTIC ACTIVITY, AND
RP   AUTOPHOSPHORYLATION.
RC   TISSUE=Fetal brain;
RX   PubMed=9748265; DOI=10.1074/jbc.273.40.25893;
RA   Becker W., Weber Y., Wetzel K., Eirmbter K., Tejedor F.J., Joost H.-G.;
RT   "Sequence characteristics, subcellular localization, and substrate
RT   specificity of DYRK-related kinases, a novel family of dual specificity
RT   protein kinases.";
RL   J. Biol. Chem. 273:25893-25902(1998).
RN   [2]
RP   SEQUENCE REVISION TO N-TERMINUS.
RA   Becker W.;
RL   Submitted (MAY-2000) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=9845759;
RA   Xia J., Yang X., Ruan Q., Pan Q., Liu C., Xie W., Deng H.;
RT   "Molecular cloning and characterization of novel protein kinase gene
RT   DYRK3.";
RL   Zhonghua Yi Xue Yi Chuan Xue Za Zhi 15:327-332(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), FUNCTION, COFACTOR,
RP   SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND INDUCTION.
RC   TISSUE=Skeletal muscle;
RX   PubMed=10779429;
RA   Lord K.A., Creasy C.L., King A.G., King C., Burns B.M., Lee J.C.,
RA   Dillon S.B.;
RT   "REDK, a novel human regulatory erythroid kinase.";
RL   Blood 95:2838-2846(2000).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Testis;
RA   Zhou Z.M.;
RT   "Cloning of the human testis-specific dual-specificity tyrosine-(Y)-
RT   phosphorylation regulated kinase 5 (DYRK5) gene.";
RL   Submitted (DEC-2000) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Raya A., de la Luna S.;
RL   Submitted (APR-2004) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   SUBCELLULAR LOCATION, AND FUNCTION.
RX   PubMed=20167603; DOI=10.1074/jbc.m110.102574;
RA   Guo X., Williams J.G., Schug T.T., Li X.;
RT   "DYRK1A and DYRK3 promote cell survival through phosphorylation and
RT   activation of SIRT1.";
RL   J. Biol. Chem. 285:13223-13232(2010).
RN   [11]
RP   SUBCELLULAR LOCATION, FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF
RP   LYS-238.
RX   PubMed=23415227; DOI=10.1016/j.cell.2013.01.033;
RA   Wippich F., Bodenmiller B., Trajkovska M.G., Wanka S., Aebersold R.,
RA   Pelkmans L.;
RT   "Dual specificity kinase DYRK3 couples stress granule
RT   condensation/dissolution to mTORC1 signaling.";
RL   Cell 152:791-805(2013).
RN   [12]
RP   FUNCTION, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, UBIQUITINATION, AND
RP   MUTAGENESIS OF LYS-238 AND 470-ARG--LYS-474.
RX   PubMed=29973724; DOI=10.1038/s41586-018-0279-8;
RA   Rai A.K., Chen J.X., Selbach M., Pelkmans L.;
RT   "Kinase-controlled phase transition of membraneless organelles in
RT   mitosis.";
RL   Nature 559:211-216(2018).
RN   [13] {ECO:0007744|PDB:5Y86}
RP   X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) IN COMPLEX WITH HARMINE, FUNCTION,
RP   CATALYTIC ACTIVITY, ACTIVITY REGULATION, PHOSPHORYLATION AT SER-350, AND
RP   MUTAGENESIS OF LYS-238 AND SER-350.
RX   PubMed=29634919; DOI=10.1016/j.jmb.2018.04.001;
RA   Kim K., Cha J.S., Cho Y.S., Kim H., Chang N., Kim H.J., Cho H.S.;
RT   "Crystal structure of human dual-specificity tyrosine-regulated kinase 3
RT   reveals new structural features and insights into its auto-
RT   phosphorylation.";
RL   J. Mol. Biol. 430:1521-1530(2018).
RN   [14]
RP   VARIANT [LARGE SCALE ANALYSIS] LEU-239.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Dual-specificity protein kinase that promotes disassembly of
CC       several types of membraneless organelles during mitosis, such as stress
CC       granules, nuclear speckles and pericentriolar material
CC       (PubMed:29973724). Dual-specificity tyrosine-regulated kinases (DYRKs)
CC       autophosphorylate a critical tyrosine residue in their activation loop
CC       and phosphorylate their substrate on serine and threonine residues
CC       (PubMed:9748265, PubMed:29634919). Acts as a central dissolvase of
CC       membraneless organelles during the G2-to-M transition, after the
CC       nuclear-envelope breakdown: acts by mediating phosphorylation of
CC       multiple serine and threonine residues in unstructured domains of
CC       proteins, such as SRRM1 and PCM1 (PubMed:29973724). Does not mediate
CC       disassembly of all membraneless organelles: disassembly of P-body and
CC       nucleolus is not regulated by DYRK3 (PubMed:29973724). Dissolution of
CC       membraneless organelles at the onset of mitosis is also required to
CC       release mitotic regulators, such as ZNF207, from liquid-unmixed
CC       organelles where they are sequestered and keep them dissolved during
CC       mitosis (PubMed:29973724). Regulates mTORC1 by mediating the
CC       dissolution of stress granules: during stressful conditions, DYRK3
CC       partitions from the cytosol to the stress granule, together with mTORC1
CC       components, which prevents mTORC1 signaling (PubMed:23415227). When
CC       stress signals are gone, the kinase activity of DYRK3 is required for
CC       the dissolution of stress granule and mTORC1 relocation to the cytosol:
CC       acts by mediating the phosphorylation of the mTORC1 inhibitor AKT1S1,
CC       allowing full reactivation of mTORC1 signaling (PubMed:23415227). Also
CC       acts as a negative regulator of EPO-dependent erythropoiesis: may place
CC       an upper limit on red cell production during stress erythropoiesis
CC       (PubMed:10779429). Inhibits cell death due to cytokine withdrawal in
CC       hematopoietic progenitor cells (PubMed:10779429). Promotes cell
CC       survival upon genotoxic stress through phosphorylation of SIRT1: this
CC       in turn inhibits p53/TP53 activity and apoptosis (PubMed:20167603).
CC       {ECO:0000269|PubMed:10779429, ECO:0000269|PubMed:20167603,
CC       ECO:0000269|PubMed:23415227, ECO:0000269|PubMed:29634919,
CC       ECO:0000269|PubMed:29973724, ECO:0000269|PubMed:9748265}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.12.1;
CC         Evidence={ECO:0000269|PubMed:23415227, ECO:0000269|PubMed:29634919,
CC         ECO:0000269|PubMed:29973724, ECO:0000269|PubMed:9748265};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.12.1; Evidence={ECO:0000269|PubMed:23415227,
CC         ECO:0000269|PubMed:29634919, ECO:0000269|PubMed:29973724,
CC         ECO:0000269|PubMed:9748265};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.12.1;
CC         Evidence={ECO:0000269|PubMed:23415227, ECO:0000269|PubMed:29634919,
CC         ECO:0000269|PubMed:29973724, ECO:0000269|PubMed:9748265};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:10779429};
CC   -!- ACTIVITY REGULATION: Protein kinase activity is activated following
CC       autophosphorylation at Tyr-369 (PubMed:9748265). Inhibited by harmine,
CC       an ATP competitive inhibitor (PubMed:29634919). Inhibited by small-
CC       compound GSK-626616 (PubMed:29973724). {ECO:0000269|PubMed:29634919,
CC       ECO:0000269|PubMed:29973724, ECO:0000269|PubMed:9748265}.
CC   -!- SUBUNIT: Interacts with SIRT1. {ECO:0000250|UniProtKB:Q922Y0}.
CC   -!- INTERACTION:
CC       O43781-2; Q9H8Y8: GORASP2; NbExp=5; IntAct=EBI-13332019, EBI-739467;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:10779429,
CC       ECO:0000269|PubMed:20167603, ECO:0000269|PubMed:29973724}. Cytoplasm
CC       {ECO:0000269|PubMed:29973724}. Nucleus speckle
CC       {ECO:0000269|PubMed:29973724}. Cytoplasmic granule
CC       {ECO:0000269|PubMed:20167603, ECO:0000269|PubMed:23415227,
CC       ECO:0000269|PubMed:29973724}. Cytoplasm, cytoskeleton, microtubule
CC       organizing center, centrosome {ECO:0000269|PubMed:29973724}.
CC       Note=Associates with membraneless organelles in the cytoplasm and
CC       nucleus (PubMed:29973724). Shuttles between cytoplasm and stress
CC       granules (PubMed:20167603). Localized predominantly on distinct
CC       speckles distributed throughout the cytoplasm of the cell
CC       (PubMed:20167603). At low concentration, showns a homogeneous
CC       distribution throughout the cytoplasm and does not condense in
CC       speckles. During oxidative and osmotic stress, localizes to stress
CC       granules (PubMed:20167603). {ECO:0000269|PubMed:20167603,
CC       ECO:0000269|PubMed:29973724}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=Long {ECO:0000303|PubMed:10779429};
CC         IsoId=O43781-1; Sequence=Displayed;
CC       Name=2; Synonyms=Short {ECO:0000303|PubMed:10779429};
CC         IsoId=O43781-2; Sequence=VSP_026178, VSP_026179;
CC   -!- TISSUE SPECIFICITY: Isoform 1: Highly expressed in testis and in
CC       hematopoietic tissue such as fetal liver, and bone marrow
CC       (PubMed:10779429). Isoform 1: Predominant form in fetal liver and bone
CC       marrow (PubMed:10779429). Isoform 1: Present at low levels in heart,
CC       pancreas, lymph node and thymus (PubMed:10779429). Isoform 2: Highly
CC       expressed in testis and in hematopoietic tissue such as fetal liver,
CC       and bone marrow (PubMed:10779429). Isoform 2: Predominant form in
CC       testis. Isoform 2: Present at low levels in heart, pancreas, lymph node
CC       and thymus (PubMed:10779429). {ECO:0000269|PubMed:10779429}.
CC   -!- INDUCTION: By EPO/erythropoietin. {ECO:0000269|PubMed:10779429}.
CC   -!- DOMAIN: The N-terminal domain, which is intrinsically disordered, is
CC       required for stress granule localization.
CC       {ECO:0000269|PubMed:23415227}.
CC   -!- PTM: Ubiquitinated at anaphase by the anaphase-promoting complex
CC       (APC/C), leading to its degradation by the proteasome.
CC       {ECO:0000269|PubMed:29973724}.
CC   -!- PTM: Protein kinase activity is activated following autophosphorylation
CC       at Tyr-369 (Probable). Autophosphorylation at Ser-350 stabilizes the
CC       protein and enhances the protein kinase activity (PubMed:9748265).
CC       {ECO:0000269|PubMed:9748265, ECO:0000305|PubMed:9748265}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CMGC Ser/Thr
CC       protein kinase family. MNB/DYRK subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; Y12735; CAA73266.2; -; mRNA.
DR   EMBL; AF186773; AAG17028.1; -; mRNA.
DR   EMBL; AF186774; AAG17029.1; -; mRNA.
DR   EMBL; AF327561; AAK16443.1; -; mRNA.
DR   EMBL; AY590695; AAT06103.1; -; mRNA.
DR   EMBL; AL591846; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471100; EAW93533.1; -; Genomic_DNA.
DR   EMBL; CH471100; EAW93534.1; -; Genomic_DNA.
DR   EMBL; BC015501; AAH15501.1; -; mRNA.
DR   CCDS; CCDS30999.1; -. [O43781-1]
DR   CCDS; CCDS31000.1; -. [O43781-2]
DR   RefSeq; NP_001004023.1; NM_001004023.1. [O43781-2]
DR   RefSeq; NP_003573.2; NM_003582.2. [O43781-1]
DR   RefSeq; XP_005273372.1; XM_005273315.4. [O43781-2]
DR   PDB; 5Y86; X-ray; 1.90 A; A=1-588.
DR   PDBsum; 5Y86; -.
DR   AlphaFoldDB; O43781; -.
DR   SMR; O43781; -.
DR   BioGRID; 114022; 10.
DR   IntAct; O43781; 28.
DR   MINT; O43781; -.
DR   STRING; 9606.ENSP00000356076; -.
DR   BindingDB; O43781; -.
DR   ChEMBL; CHEMBL4575; -.
DR   GuidetoPHARMACOLOGY; 2012; -.
DR   iPTMnet; O43781; -.
DR   PhosphoSitePlus; O43781; -.
DR   BioMuta; DYRK3; -.
DR   jPOST; O43781; -.
DR   MassIVE; O43781; -.
DR   MaxQB; O43781; -.
DR   PaxDb; O43781; -.
DR   PeptideAtlas; O43781; -.
DR   PRIDE; O43781; -.
DR   ProteomicsDB; 49168; -. [O43781-1]
DR   ProteomicsDB; 49169; -. [O43781-2]
DR   Antibodypedia; 34587; 238 antibodies from 28 providers.
DR   DNASU; 8444; -.
DR   Ensembl; ENST00000367106.1; ENSP00000356073.1; ENSG00000143479.18. [O43781-2]
DR   Ensembl; ENST00000367108.7; ENSP00000356075.3; ENSG00000143479.18. [O43781-2]
DR   Ensembl; ENST00000367109.8; ENSP00000356076.2; ENSG00000143479.18. [O43781-1]
DR   GeneID; 8444; -.
DR   KEGG; hsa:8444; -.
DR   MANE-Select; ENST00000367109.8; ENSP00000356076.2; NM_003582.4; NP_003573.2.
DR   UCSC; uc001hei.4; human. [O43781-1]
DR   CTD; 8444; -.
DR   DisGeNET; 8444; -.
DR   GeneCards; DYRK3; -.
DR   HGNC; HGNC:3094; DYRK3.
DR   HPA; ENSG00000143479; Tissue enhanced (testis).
DR   MIM; 603497; gene.
DR   neXtProt; NX_O43781; -.
DR   OpenTargets; ENSG00000143479; -.
DR   PharmGKB; PA27551; -.
DR   VEuPathDB; HostDB:ENSG00000143479; -.
DR   eggNOG; KOG0667; Eukaryota.
DR   GeneTree; ENSGT00940000159878; -.
DR   HOGENOM; CLU_000288_5_13_1; -.
DR   InParanoid; O43781; -.
DR   OMA; CDDPTFI; -.
DR   OrthoDB; 870358at2759; -.
DR   PhylomeDB; O43781; -.
DR   TreeFam; TF314624; -.
DR   BRENDA; 2.7.12.1; 2681.
DR   PathwayCommons; O43781; -.
DR   SignaLink; O43781; -.
DR   SIGNOR; O43781; -.
DR   BioGRID-ORCS; 8444; 11 hits in 1114 CRISPR screens.
DR   ChiTaRS; DYRK3; human.
DR   GeneWiki; DYRK3; -.
DR   GenomeRNAi; 8444; -.
DR   Pharos; O43781; Tchem.
DR   PRO; PR:O43781; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; O43781; protein.
DR   Bgee; ENSG00000143479; Expressed in type B pancreatic cell and 150 other tissues.
DR   ExpressionAtlas; O43781; baseline and differential.
DR   Genevisible; O43781; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0010494; C:cytoplasmic stress granule; IDA:UniProtKB.
DR   GO; GO:0005856; C:cytoskeleton; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0016607; C:nuclear speck; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0000242; C:pericentriolar material; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB.
DR   GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0004712; F:protein serine/threonine/tyrosine kinase activity; IEA:UniProtKB-EC.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IEA:UniProtKB-KW.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0051301; P:cell division; IEA:UniProtKB-KW.
DR   GO; GO:0030218; P:erythrocyte differentiation; IDA:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0043518; P:negative regulation of DNA damage response, signal transduction by p53 class mediator; IEA:Ensembl.
DR   GO; GO:0035063; P:nuclear speck organization; IDA:UniProtKB.
DR   GO; GO:1903008; P:organelle disassembly; IDA:UniProtKB.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IBA:GO_Central.
DR   GO; GO:0018107; P:peptidyl-threonine phosphorylation; IBA:GO_Central.
DR   GO; GO:1902751; P:positive regulation of cell cycle G2/M phase transition; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0080135; P:regulation of cellular response to stress; IMP:UniProtKB.
DR   GO; GO:1903432; P:regulation of TORC1 signaling; IMP:UniProtKB.
DR   GO; GO:0035617; P:stress granule disassembly; IDA:UniProtKB.
DR   Gene3D; 3.30.10.30; -; 1.
DR   InterPro; IPR042521; DYRK.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell cycle; Cell division;
KW   Cytoplasm; Cytoskeleton; Kinase; Magnesium; Metal-binding; Mitosis;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase; Tyrosine-protein kinase;
KW   Ubl conjugation.
FT   CHAIN           1..588
FT                   /note="Dual specificity tyrosine-phosphorylation-regulated
FT                   kinase 3"
FT                   /id="PRO_0000085938"
FT   DOMAIN          209..522
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          1..188
FT                   /note="Disordered"
FT                   /evidence="ECO:0000305|PubMed:23415227"
FT   MOTIF           468..481
FT                   /note="Nuclear localization signal"
FT                   /evidence="ECO:0000269|PubMed:29973724"
FT   ACT_SITE        335
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         215..223
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000305|PubMed:29634919"
FT   BINDING         238
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000269|PubMed:23415227, ECO:0000269|PubMed:29634919"
FT   BINDING         288..291
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000305|PubMed:29634919"
FT   MOD_RES         350
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:29634919"
FT   MOD_RES         369
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:Q922Y0"
FT   VAR_SEQ         1..20
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:10779429,
FT                   ECO:0000303|PubMed:15489334, ECO:0000303|Ref.5"
FT                   /id="VSP_026178"
FT   VAR_SEQ         21..26
FT                   /note="PPQQRR -> MKWKEK (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:10779429,
FT                   ECO:0000303|PubMed:15489334, ECO:0000303|Ref.5"
FT                   /id="VSP_026179"
FT   VARIANT         239
FT                   /note="M -> L"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040464"
FT   MUTAGEN         238
FT                   /note="K->M: Kinase dead; Induces formation of stress
FT                   granules-like in absence of stress. Impaired dissolution of
FT                   membraneless organelles during mitosis, such as stress
FT                   granules, nuclear speckles and pericentriolar material."
FT                   /evidence="ECO:0000269|PubMed:23415227,
FT                   ECO:0000269|PubMed:29634919, ECO:0000269|PubMed:29973724"
FT   MUTAGEN         350
FT                   /note="S->A: Decreased stability of the protein."
FT                   /evidence="ECO:0000269|PubMed:29634919"
FT   MUTAGEN         350
FT                   /note="S->E,D: Phosphomimetic mutant; increased stability
FT                   of the protein."
FT                   /evidence="ECO:0000269|PubMed:29634919"
FT   MUTAGEN         470..474
FT                   /note="RRGKK->AAGAA: Abolishes localization to the nucleus,
FT                   leading to impaired dissolution of nuclear speckles during
FT                   mitosis."
FT                   /evidence="ECO:0000269|PubMed:29973724"
FT   CONFLICT        313
FT                   /note="R -> H (in Ref. 9; AAH15501)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        396
FT                   /note="G -> R (in Ref. 1; CAA73266)"
FT                   /evidence="ECO:0000305"
FT   HELIX           143..149
FT                   /evidence="ECO:0007829|PDB:5Y86"
FT   TURN            150..153
FT                   /evidence="ECO:0007829|PDB:5Y86"
FT   HELIX           156..161
FT                   /evidence="ECO:0007829|PDB:5Y86"
FT   HELIX           162..164
FT                   /evidence="ECO:0007829|PDB:5Y86"
FT   HELIX           185..188
FT                   /evidence="ECO:0007829|PDB:5Y86"
FT   TURN            206..208
FT                   /evidence="ECO:0007829|PDB:5Y86"
FT   STRAND          209..218
FT                   /evidence="ECO:0007829|PDB:5Y86"
FT   STRAND          221..228
FT                   /evidence="ECO:0007829|PDB:5Y86"
FT   TURN            229..232
FT                   /evidence="ECO:0007829|PDB:5Y86"
FT   STRAND          233..240
FT                   /evidence="ECO:0007829|PDB:5Y86"
FT   HELIX           244..263
FT                   /evidence="ECO:0007829|PDB:5Y86"
FT   TURN            266..269
FT                   /evidence="ECO:0007829|PDB:5Y86"
FT   STRAND          274..280
FT                   /evidence="ECO:0007829|PDB:5Y86"
FT   STRAND          283..288
FT                   /evidence="ECO:0007829|PDB:5Y86"
FT   HELIX           295..301
FT                   /evidence="ECO:0007829|PDB:5Y86"
FT   TURN            302..304
FT                   /evidence="ECO:0007829|PDB:5Y86"
FT   HELIX           309..328
FT                   /evidence="ECO:0007829|PDB:5Y86"
FT   HELIX           338..340
FT                   /evidence="ECO:0007829|PDB:5Y86"
FT   STRAND          341..345
FT                   /evidence="ECO:0007829|PDB:5Y86"
FT   STRAND          351..353
FT                   /evidence="ECO:0007829|PDB:5Y86"
FT   HELIX           356..358
FT                   /evidence="ECO:0007829|PDB:5Y86"
FT   HELIX           373..375
FT                   /evidence="ECO:0007829|PDB:5Y86"
FT   HELIX           378..382
FT                   /evidence="ECO:0007829|PDB:5Y86"
FT   HELIX           389..404
FT                   /evidence="ECO:0007829|PDB:5Y86"
FT   HELIX           414..425
FT                   /evidence="ECO:0007829|PDB:5Y86"
FT   HELIX           430..434
FT                   /evidence="ECO:0007829|PDB:5Y86"
FT   HELIX           439..441
FT                   /evidence="ECO:0007829|PDB:5Y86"
FT   STRAND          452..456
FT                   /evidence="ECO:0007829|PDB:5Y86"
FT   STRAND          462..465
FT                   /evidence="ECO:0007829|PDB:5Y86"
FT   HELIX           483..486
FT                   /evidence="ECO:0007829|PDB:5Y86"
FT   TURN            487..489
FT                   /evidence="ECO:0007829|PDB:5Y86"
FT   HELIX           493..502
FT                   /evidence="ECO:0007829|PDB:5Y86"
FT   HELIX           507..509
FT                   /evidence="ECO:0007829|PDB:5Y86"
FT   HELIX           513..518
FT                   /evidence="ECO:0007829|PDB:5Y86"
FT   TURN            520..522
FT                   /evidence="ECO:0007829|PDB:5Y86"
SQ   SEQUENCE   588 AA;  65714 MW;  9950F51C39AFED82 CRC64;
     MGGTARGPGR KDAGPPGAGL PPQQRRLGDG VYDTFMMIDE TKCPPCSNVL CNPSEPPPPR
     RLNMTTEQFT GDHTQHFLDG GEMKVEQLFQ EFGNRKSNTI QSDGISDSEK CSPTVSQGKS
     SDCLNTVKSN SSSKAPKVVP LTPEQALKQY KHHLTAYEKL EIINYPEIYF VGPNAKKRHG
     VIGGPNNGGY DDADGAYIHV PRDHLAYRYE VLKIIGKGSF GQVARVYDHK LRQYVALKMV
     RNEKRFHRQA AEEIRILEHL KKQDKTGSMN VIHMLESFTF RNHVCMAFEL LSIDLYELIK
     KNKFQGFSVQ LVRKFAQSIL QSLDALHKNK IIHCDLKPEN ILLKHHGRSS TKVIDFGSSC
     FEYQKLYTYI QSRFYRAPEI ILGSRYSTPI DIWSFGCILA ELLTGQPLFP GEDEGDQLAC
     MMELLGMPPP KLLEQSKRAK YFINSKGIPR YCSVTTQADG RVVLVGGRSR RGKKRGPPGS
     KDWGTALKGC DDYLFIEFLK RCLHWDPSAR LTPAQALRHP WISKSVPRPL TTIDKVSGKR
     VVNPASAFQG LGSKLPPVVG IANKLKANLM SETNGSIPLC SVLPKLIS
//
